Page 9 - Directed Issue News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Medivir Proposes Directed Issue of Approximately SEK 28 Million to the Company's Existing Specialist Investor LINC News provided by Share this article HUDDINGE, Sweden, Feb. 7, 2021 /PRNewswire/ -- The Board of Directors in Medivir AB (publ) ("Medivir" or the "Company") has decided to summon an extraordinary general meeting on 11 March 2021 to propose a directed issue (the "Directed Issue") to the Company's existing specialist investor LINC AB ("LINC"), controlled by the Company's board member Bengt Julander. In the rights issue, from which the preliminary results was announced on 5 Februar...

Cantargia has completed a directed share issue of approximately SEK 564 million NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA, AUSTRALIA, CANADA, JAPAN OR ANY OTHER JURISDICTION IN WHICH THE RELSEASE, DISTRIBUTION OR PUBLICATION WOULD BE UNLAWFUL OR REQUIRE REGISTRATION OR ANY OTHER MEASURES BEYOND WHAT IS REQUIRED UNDER SWEDISH LAW. STOCKHOLM, Dec. 16, 2020 /PRNewswire/ -- The board of directors of Cantargia AB (publ) ("Cantargia" or the "Company") (Nasdaq Stockholm: CANTA) has, as indicated in the Company...

Cantargia announces intention of a directed share issue STOCKHOLM, Dec. 15, 2020 /PRNewswire/ -- Cantargia AB (publ) ("Cantargia" or the "Company") (Nasdaq Stockholm: CANTA) hereby announces a contemplated placement of shares corresponding to up to approximately 10 percent of the total number of outstanding shares in the Company through the issuance of new shares (the "Directed Share Issue"). The Directed Share issue will be directed to Swedish and international institutional investors. Cantargia has engaged Carnegie Investment Bank AB (publ), Kempen & Co and Oppenheimer & Co. Inc. to act as...

/PRNewswire/ -- OncoZenge AB (publ) ("OncoZenge"), Moberg Pharma AB (publ)'s subsidiary, has today resolved on a directed share issue in accordance with the...